Russell Investments Group’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-3,121
| Closed | -$120K | – | 3680 |
|
|
2023
Q2 | $120K | Sell |
3,121
-15,571
| -83% | -$400K | ﹤0.01% | 2570 |
|
|
2023
Q1 | $433K | Buy |
18,692
+3,301
| +21% | +$78.7K | ﹤0.01% | 2306 |
|
|
2022
Q4 | $403K | Hold |
15,391
| – | – | ﹤0.01% | 2351 |
|
|
2022
Q3 | $302K | Hold |
15,391
| – | – | ﹤0.01% | 2426 |
|
|
2022
Q2 | $269K | Hold |
15,391
| – | – | ﹤0.01% | 2475 |
|
|
2022
Q1 | $251K | Sell |
15,391
-2,458
| -14% | -$33.4K | ﹤0.01% | 2414 |
|
|
2021
Q4 | $291K | Buy |
17,849
+2,458
| +16% | +$35K | ﹤0.01% | 2618 |
|
|
2021
Q3 | $196K | Hold |
15,391
| – | – | ﹤0.01% | 2779 |
|
|
2021
Q2 | $217K | Hold |
15,391
| – | – | ﹤0.01% | 2885 |
|
|
2021
Q1 | $239K | Buy |
+15,391
| New | +$251K | ﹤0.01% | 2780 |
|
|
2020
Q4 | – | Sell |
-18,292
| Closed | -$221K | – | 3239 |
|
|
2020
Q3 | $221K | Hold |
18,292
| – | – | ﹤0.01% | 2740 |
|
|
2020
Q2 | $210K | Hold |
18,292
| – | – | ﹤0.01% | 2700 |
|
|
2020
Q1 | $249K | Sell |
18,292
-9,897
| -35% | -$117K | ﹤0.01% | 2467 |
|
|
2019
Q4 | $166K | Buy |
+28,189
| New | +$153K | ﹤0.01% | 2764 |
|
|
2017
Q4 | – | Sell |
-2,327
| Closed | -$124K | – | 3027 |
|
|
2017
Q3 | $124K | Sell |
2,327
-4,827
| -67% | -$287K | ﹤0.01% | 2745 |
|
|
2017
Q2 | $408K | Buy |
+7,154
| New | +$359K | ﹤0.01% | 2490 |
|
|
2017
Q1 | – | Sell |
-5,545
| Closed | -$324K | – | 3107 |
|
|
2016
Q4 | $324K | Buy |
+5,545
| New | +$335K | ﹤0.01% | 2595 |
|
Russell Investments Group's KDNY Position: Q3 2023 in Review
Russell Investments Group sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q3 2023, closing a stake of 3,121 shares — an estimated $120K sold.
Russell Investments Group first reported a position in KDNY in Q4 2016 and held it in 17 quarters. The position peaked at $433K in Q1 2023. 2 funds tracked by Wall St. Rank hold KDNY as of Q3 2023.
- Russell Investments Group reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
- Russell Investments Group sold 3,121 Chinook Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $120K.
- Russell Investments Group first reported a position in Chinook Therapeutics, Inc. Common Stock in Q4 2016 and held it in 17 quarters.
- Russell Investments Group's Chinook Therapeutics, Inc. Common Stock position peaked at $433K in Q1 2023.
- 2 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q3 2023.
Based on Russell Investments Group's 13F filing for Q3 2023, filed 13 Nov 2023.